JAMESTOWN
10.11.2020 10:02:17 CET | Business Wire | Press release
Global real estate company Jamestown today announced the acquisition of three historic office buildings in the up-and-coming Mülheim area of Cologne – the city that is home to Jamestown’s European headquarters. The acquisition marks the firm’s first-ever acquisition in Germany, and its second in Europe in less than a year.
Formerly an industrial neighborhood, Mülheim has, over the past decade, become a thriving area of redevelopment that attracts companies seeking creative spaces. Constructed between 1890 and 1914, the buildings at Schanzenstrasse 22, 24, and 28 are home to a mix of multi-media and entertainment companies, including prominent television production company Brainpool TV. The 34,545-square meter buildings are an attractive blend of post-industrial architecture. Jamestown purchased the buildings with two institutional investors from a group of private investors.
“We have been investing in US real estate from Cologne for 37 years. Our first project in Germany is an important milestone for Jamestown. One of our core competencies at Jamestown is the revitalization of old industrial buildings and we see great potential for this in Europe as well, ” said Christoph Kahl, Chairman of Jamestown.
Jamestown has a long track record of revitalizing historic, industrial buildings into neighborhood destinations and office hubs specializing in technology and content creation. This development strategy has proven to be an economically, socially, and environmentally responsible alternative to new construction. Jamestown prides itself on preserving cities’ industrial pasts, while bringing new life into local communities. Its leadership team continues to see many opportunities to expand this adaptive reuse strategy across Europe, with its rich industrial heritage and strong urban cultures.
“We are excited to add Schanzenstrasse to our growing European footprint. Technology, media, and content firms are resilient, durable sectors that are thriving in the current market. Our focus is on mixed-use projects that create ecosystems where businesses can connect to one another and the consumer. Mülheim, and our other neighbors, are part of that ecosystem,” said Michael Phillips, President of Jamestown.
Jamestown worked with DLA Piper and the seller with McDermott, Will & Emery for legal counsel. The seller was represented by Tresono Family Office. The property will be managed by Apleona Real Estate GmbH.
Since it was established in 1983, Jamestown has been a recognizable name in Germany for operating real estate funds and as a leading landlord and property manager of mixed-use projects in the U.S. that offer commercial office, residential, and retail spaces.
Jamestown made its first European acquisition in December 2019, when it bought the historic Groot Handelsgebouw in Rotterdam, the Netherlands. The company’s roughly $12 billion / EUR 10 billion portfolio includes some of the most iconic buildings and landmarks in the U.S. including One Times Square in New York, Ghirardelli Square in San Francisco, and Ponce City Market in Atlanta.
###
About Jamestown
Jamestown was established in 1983 as an investment and management company focused on income-producing real estate in the United States. Since then, Jamestown has grown its portfolio of assets in key markets throughout the U.S. and expanded its investment footprint to South America and Europe. Jamestown's capabilities include acquisitions, capital markets, property management, asset management, retail leasing, design, sustainability, and risk management. Jamestown has headquarters in Cologne, Germany and Atlanta, Georgia and offices in Amsterdam, New York, Boston, San Francisco, Los Angeles, and Bogota, Colombia. For more information, visit www.jamestownlp.com
.
Photos:
https://jamestown.canto.com/b/G7E1O
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005543/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
